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INTRODUCTION 
Idiosyncratic drug-induced liver injury (DILI) is an adverse 
drug reaction in the liver that is differentiated from intrinsic 
DILI by not showing simple dose-dependency. Idiosyncratic 
DILI has become a major clinical challenge because of its high 
morbidity, mortality, unpredictable nature, frequent hospital-
ization, and need for liver transplantation.1 Given the low inci-
dence of idiosyncratic DILI, it cannot be detected in preclinical 
testing or clinical trials.
Prospective population-based epidemiological studies re-
ported an annual crude incidence of 13.9 cases per 100,000 in-
habitants in France in 1997-2000,2 12 cases per 100,000 inhabit-
ants in Korea in 2005-2007,3 and 19.1 cases per 100,000 inhabit-
ants in Iceland in 2010-2011.4 Antibiotics, nonsteroidal anti-in-
flammatory drugs, and isoniazid are the most common medi-
cations associated with idiosyncratic DILI. In Asian countries, 
herbal medications are the principal cause of DILI.3 A retro-
spective population-based study in the UK estimated the inci-
dence of DILI as 2.4 per 100,000 inhabitants,5 showing 6 times 
lower incidence in the prospective study of DILI. 
Based on the ratio of abnormalities in liver function (R ratio, a 
ratio of the alanine aminotransferease [ALT] to alkaline phos-
phatase [ALP] relative to their respective upper limits of normal 
[ULN]), DILI can be categorized as hepatocellular (R>5), cho-
lestatic (R<2), or mixed type (2<R<5) of liver injury.6 It can be 
applied to classify DILI into endotypes for genetic association 
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studies. 
Risk factors for DILI are complex; however, host genetic, im-
munological, and metabolic factors play an important role. 
DILI is more likely to occur in the elderly,7 females,4 and pa-
tients with underlying chronic liver disease.8 Several character-
istics of a drug, such as medication dose, drug lipophilicity, and 
extent of hepatic metabolism, also play a role. Environmental 
factors, such as alcohol intake, pre-existing disease, and viral 
infections, are important patient characteristics. Genetic factors 
are associated with genes that influence drug metabolism and/
or immunological reactions to the drug. The frequency, severi-
ty, and clinical manifestations vary according to the drug, the 
underlying disease, and ethnicity of the patient.
Although mechanisms for idiosyncratic DILI remain unclear, 
the delayed onset of the reaction and genetic associations be-
tween the expression of particular HLA molecules and suscep-
tibility to drug-induced liver injury9-12 are indicative of an im-
munogenetic basis.
The present review focuses on current pharmacogenomics, 
recent advances in mechanistic studies, and newly identified 
biomarkers for idiosyncratic DILI.
Genetic predisposition to idiosyncratic DILI
Genetic association studies on DILI remain challenging be-
cause of the relative rarity of this condition, phenotypic diversi-
ty in DILI cohorts, ethnic diversity, and complex culprit drugs. 
The limitations are magnified when performing genome-wide 
association studies on DILI because it requires sufficient study 
subjects to reach a genome-wide level of significance, as well as 
a replication study cohort based on different populations to ex-
clude frequently occurring false-positive associations. To over-
come these limitations, international multicenter research net-
works have been established in accordance with case definition 
and phenotype standardization as well as with regard to grad-
ing the severity of DILI.13 Multicenter research networks for 
studying idiosyncratic DILI have been established in the USA 
(DILIN),14 UK (DILIGEN),10 Europe (EUDRAGENE),15 Spain 
(Spain DILI registry),16 Canada (CPNDS),17 and the internation-
al Severe Adverse Event consortium (SAE).18
An association between a specific human leukocyte antigen 
(HLA) allele with idiosyncratic DILI has been reported for 
several drugs (e.g., flucloxacillin [B*57:01],10 ximelagatran 
[DRB1*07:01 and HLA-DQA1*02],9 co-amoxiclave [DRB1*15: 
01],12,19,20 lumiracoxib [DRB1*15:01],11 lapatinib [HLA-DRB1* 
0701-DQA1*0202/DQB1*0203],21 antituberculosis drugs [HLA-
DQB1*0502],22 and isoniazid [HLA-DRB1*03], rifampin [HLA-
DQA1*0102], and ethambutol [HLA-DQB1*0201]23). 
Recently, in silico analysis of HLA alleles associated with DILI 
revealed a link between different HLA alleles.24 DILI caused by 
several chemically unrelated drugs, such as ticlopidine, lumira-
coxib, and co-amoxiclav, resides on similar haplotypes, namely, 
DQB1*0604-DQA1*0102 and DQB1*0602-DQA1*0102. Given 
the same peptide binding capability between DQB1*0604 and 
DQB1*0602, common causal alleles within the major histo-
compatibility complex (MHC) class II may be genetic predis-
posing factors for DILI. However, further genotyping is required 
using next-generation sequencing techniques. 
New insights from GWAS can provide good clinical utility by 
avoiding the use of potentially harmful drugs in susceptible pa-
tients having an HLA risk allele.25,26 For example, avoidance of 
carbamazepine therapy in HLA-B*1502-positive patients has 
reduced the incidence of a potentially severe cutaneous hyper-
sensitivity, such as Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) in Taiwan.25 HLA-B*5701 testing 
significantly reduces the incidence of abacavir-induced hyper-
sensitivity.26 The food and drug administration (FDA) recom-
mended pretreatment HLA screening for abacavir and carbam-
azepine therapies and this has been helpful for the manage-
ment of adverse events. Furthermore, a validation study of 
HLA-DRB1*0701 using a prospective, randomized, placebo-
controlled clinical trial of lapatinib monotherapy in early-stage 
breast cancer demonstrated good clinical utility for HLA-
DRB1*0701 typing for the management of patients experienc-
ing hepatotoxicity during lapatinib treatment.27 HLA-DRB1 
*0701 allele carriers show increased ALT above background lev-
els in the placebo treatment, which supports a previous finding 
of HLA-DRB1*0701 as a predictive risk factor for lapatinib-in-
duced liver injury. 
However, recent studies on predictive genetic testing for DILI 
demonstrated a low positive predictive value of 0.12%, even in 
the strongest association of HLA-B*5701 with flucloxacillin-in-
duced DILI.28 Therefore, a multidisciplinary approach that re-
lates immune responses to clinical outcomes is required to im-
prove predictability by combining biomarkers with HLA typing 
tests. The association between particular HLA alleles and sus-
ceptibility to DILI drives studies on how small drugs can induce 
drug-specific T cell responses, which are restricted by the host 
HLA allele. 
Predisposition to immunological drug reactions
The association of a specific HLA allele with DILI gives rise to 
several major questions: (1) how are small drugs antigenic (i.e., 
interact with MHC proteins to activate T lymphocytes); (2) how 
and why do drug-specific T cell responses arise in a small por-
tion of patients; and (3) how is a specific immune response re-
stricted by host HLA alleles? 
T lymphocytes are thought to be involved in the pathogenesis 
of certain immune-mediated adverse drug reactions, indirectly 
causing tissue damage through the action of cytokines or di-
rectly by the secretion of cytolytic molecules (e.g., perforin, gra-
nulysin, and FAS ligand). To stimulate a T-cell response, a drug 
must act as an antigen and ligate specific T-cell receptors that 
ultimately results in the activation of specific T cells. 
Hapten theory―originating from the studies of Landsteiner 
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and Jacobs in the 1930s relating skin sensitization potential to 
protein reactivity 29―states that a drug must bind irreversibly to 
self-protein to break immune tolerance. T cells are subsequent-
ly stimulated by peptides liberated from the modified protein 
following antigen processing. Drugs have also been shown to 
be associated directly with peptides embedded in the MHC to 
stimulate a T-cell response.30-37 Despite this, very few studies 
have attempted to define drug-protein antigens in patients and 
hence relate the chemistry of antigen formation to the immune 
response.
Drug antigenicity 
Traditionally, drugs were thought to be too small to interact 
directly with MHC molecules. For this reason, hapten forma-
tion is believed to be an important step in the generation of 
drug-specific immune responses. With reference to T cell-me-
diated reactions, the protein conjugate is broken down or “pro-
cessed” by antigen-presenting cells, liberating antigenic pep-
tides that are associated with MHC molecules prior to presen-
tation to T cells. For β-lactam antibiotics, the β-lactam ring is 
targeted directly by nucleophilic lysine residues on proteins, 
leading to ring opening and binding of the penicilloyl group.38-40 
Most of the other drug classes associated with a high incidence 
of immunological reactions are chemically inert; however, 
through normal processes of drug metabolism, protein-reac-
tive intermediates may be generated.41-43 Using advanced tech-
nologies, such as mass spectrometry, it is possible to define the 
chemistry of drug-protein conjugation in patients and the na-
ture of the drug-derived epitopes, which can function as an an-
tigen to stimulate T cells.44-48 
There is another mechanism underlying drug-specific T-cell 
activation. This concept, referred to as the “pharmacological in-
teraction of drugs with immune receptors (p-i concept),” states 
that drugs by themselves act as antigens interacting in a revers-
ible fashion with immunological receptors.49 By characterizing 
T-cell clones from patients with immunological drug reactions, 
the pharmacophore of several drugs, including sulfamethoxa-
zole,30,34,50 carbamazepine,51,52 abacavir,53 and penicillin,54 have 
been shown to interact with MHC molecules directly and pro-
vide a sufficiently strong signal to stimulate T cells. 
Recently, new in vitro assays using cells from healthy volun-
teers have been designed to study drug antigenicity.55 Several 
key elements are required for the initiation of drug-specific T-
cell responses, and each must be incorporated into an in vitro 
assay: (1) drug delivery in an appropriate antigenic form, (2) 
the provision of maturation signals for professional antigen-
presenting cells, and (3) appropriate co-stimulatory/co-inhibi-
tory receptor ligand interactions. Furthermore, one must con-
sider the phenotype and functionality of antigen-specific T 
cells, appropriateness of the T-cell readout, and the genetic 
background of the volunteer. This recently developed assay re-
lies on the isolation and culture of highly pure T-cell and anti-
gen presenting-cell populations. Immature monocyte-derived 
dendritic cells and naive T cells are used as antigen presenting 
cells and responder cells, respectively. After a 10-day culture 
period, T cells are re-exposed to the drug antigen and dendritic 
cells, and antigen specificity is measured shortly thereafter. In 
addition to classical readouts for proliferation, cytokine secre-
tion, and cytotoxicity, a change in phenotype from naive to 
memory can be quantified using flow cytometry.
Drug immunogenicity 
Not all carriers of the risk allele develop pathogenic immuno-
logical drug reactions. To initiate an immune response, 2 path-
ways must be triggered, namely, the antigenic signal, sensed by 
specific T-cell receptors, and the maturation signal, sensed by 
dendritic cells, which subsequently provide co-stimulatory sig-
nals to T cells upon activation. The latter is thought to function 
as a “danger signal” regarding the “drug-inflammation interac-
tion,” suggesting that a modest inflammation can enhance 
some drug-induced immunogenicity and potentially predis-
pose an individual to hepatotoxicity.56 Our understanding of 
drug-dendritic cell interactions and the role of bystander cells 
in the provision of dendritic-cell maturation signaling is limit-
ed.57-59 By establishing an HLA-typed cell bank24 and the avail-
ability of a novel assay to detect the stimulation of naïve T cells 
with drugs, it is beginning to become possible to define wheth-
er an environment rich in dendritic-cell maturation signals 
contributes to the conversion of antigenic signals into an im-
mune response.  
For T cells to exert a cytotoxic response in a particular organ, 
they must be recruited from the circulation. The expression of 
specific chemokines and their subsequent interaction with 
chemokine receptors on the surface of lymphocytes is known 
to promote T-cell migration through the endothelium and into 
tissues. T cells infiltrating skin express high levels of cutaneous 
lymphocyte-associated antigen (CLA) and the chemokine re-
ceptors CCR4 and CCR10, and drug-specific T cells from pa-
tients with cutaneous drug hypersensitivity reactions express 
high levels of these receptors.52,60-62 Although the expression of 
chemokine receptors on liver homing T cells is less defined, 
CXCR3, CCR5, CCR9, and CXCR6 have been found on T cells 
isolated from patients with various forms of liver disease.63 
Lymphocytes from a patient with trimethoprim-induced liver 
injury express high levels of CXCR3 and CCR9, but only low lev-
els of skin-homing receptors.64 Thus, it may be possible to mon-
itor chemokine receptor expression profiles to define the role of 
drug-specific T cells in hepatic (CXCR3, CXCR6, CCR5, and 
CCR9) and cutaneous (CCR4 and CCR10) side-effects of im-
munological drug reactions.63
HLA allele-specific immune response
Several studies suggest that the hapten/pro-hapten immuno-
genic complex may be restricted to a specific HLA allotype.65 
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First, a haptenated peptide with a drug occupies an anchor 
pocket in a specific HLA molecule. Second, incorporation of 
the drug or metabolite into an anchor pocket of the associated 
HLA molecule can alter its peptide-binding groove and gener-
ate a shift in the peptide repertoire it can subsequently bind. 
Third, a modification of a peptide that specifically binds a par-
ticular HLA allotype by solvent-exposed side chains of the drug. 
Using affinity chromatography via immobilized monoclonal 
antibodies specific for the HLA allotypes, cell-surface HLA-pep-
tide complexes can be isolated, and peptide ligand can be dis-
sociated from HLA proteins. The peptide can be identified us-
ing tandem mass spectrometry and then used to detect the spe-
cific interaction with the HLA molecule based on peptide-bind-
ing assays.66,67 However, to date the identity of naturally eluted 
T-cell stimulatory hapten-peptide complexes is not known for 
drugs associated with a high incidence of idiosyncratic DILI.
Immunologic basis for the pathogenesis of DILI
The presence of drug-responsive T lymphocytes in blood and 
liver biopsies of patients with DILI supports their involvement 
in disease pathogenesis. In 1997, Maria and Victorino demon-
strated lymphocyte responses to drugs in over 50% of patients 
with DILI. The detection of drug-specific lymphocyte respons-
es in certain patients with liver injury suggests that drug reac-
tions are immune-mediated. Histological examination of in-
flamed liver tissue from a patient with a sulfasalazine-induced 
drug reaction with eosinophilia and systemic symptoms 
(DRESS) syndrome revealed infiltration of granzyme B secret-
ing T lymphocytes.69 This finding supports a direct role of drug-
responsive T lymphocytes in the pathogenesis of DILI.
The characterization of the phenotype and function of drug-
responsive T lymphocytes has been reported in patients with 
trimethoprim-induced liver injury.64 The proliferation of CD4+ 
and CD8+ T cells against trimethoprim is reported, and the pro-
liferative response is associated with enhanced IFN-γ and IL-13 
secretion. 
Recent studies on flucloxacillin-induced liver injury70,71 sug-
gest 2 distinct immunological mechanisms based on hapten 
and p-i concepts. Monshi et al.70 reported that flucloxacillin-re-
sponsive T cells stimulate IFN-γ secretion from peripheral 
blood mononuclear cells (PBMC) isolated from DILI patients 
as well as healthy volunteers expressing HLA-B*5701. Covalent 
binding of flucloxacilin to specific lysine residues on albumin is 
also observed using mass spectrometric analysis. The level of 
drug binding showed a significant correlation with the prolifer-
ative response of T-cell clones against flucloxacillin. The T-cell 
response is dependent on antigen processing, which suggests 
that T cells may be activated by peptides derived from the hap-
tenated protein. Furthermore, naïve T cells isolated from 
healthy volunteers expressing HLA-B*5701 are found to be acti-
vated by flucloxacillin. The drug-specific T-cell response is de-
pendent on the presence of antigen-presenting cells expressing 
HLA-B*5701.
Wuillemin et al.71 suggested that HLA haplotypes determine 
distinct immunologic mechanisms, hapten- or p-i, based T-cell 
reactivity toward flucloxacillin. They used T-cell assays with 
PBMC from healthy human donors to evaluate mechanisms of 
drug antigen presentation by characterizing 3 aspects: (1) sta-
ble or labile presentation of flucloxacillin by antigen presenting 
cells, (2) dependency on proteasomal processing, and (3) acti-
vation kinetics of T-cell clones on the stimulation of flucloxacil-
lin in solution. In healthy volunteers expressing HLA-B*5701, 
flucloxacillin is presented in a labile manner, independent of 
antigen processing, and restricted by the host HLA allele, HLA-
B*5701. Thus, p-i based T-cell reactivity is found in HLA-B*5701 
carriers. On the other hand, in healthy volunteers expressing 
other HLA-B alleles, T-cell reactivity against flucloxacillin is de-
pendent on antigen processing, suggestive of a hapten mecha-
nism. However, Yassen et al.72 demonstrated preferential T-cell 
responses to flucloxacillin-hapten in patients with liver injury 
expressing HLA-B*5701 via a hapten mechanism. This finding 
suggested promiscuous T-cell responses to flucloxacillin and 
flucloxacillin-hapten may co-exist and predominant T-cell re-
sponse may be affected by individual immunological factors. 
Furthermore, the infiltration of cytotoxic CD8+ T lymphocytes is 
found in the liver biopsies of a patient with flucloxacillin-in-
duced liver injury,73 where cytotoxic T-cells could kill hepato-
cytes in a perforin/granzyme B-dependent manner. Moreover, 
bystander killing caused by FasL could lead to exacerbation of 
liver injury caused by flucloxacillin.73 
An alternative hypothesis has been suggested as a mecha-
nism behind interactions between drug and HLA molecules in 
abacavir-induced hypersensitivity.74-76 Abacavir can bind inside 
the peptide-binding groove of HLA-B*5701, changing the 
shape, finally leading to the alteration in the repertoire of pep-
tide that can bind HLA-B*5701. However, there has been no ex-
perimental evidence supporting this hypothesis as a mecha-
nism for DILI. In particular, Norcross et al.76 reported that anti-
gen presenting cell exposure to flucloxacillin does not alter the 
repertoire of HLA-B*5701 binding peptides displayed on the 
cell surface. 
In our most recent study, we compared/contrasted β-lactam 
and β-lactam hapten-specific T-cell responses, but importantly 
focused on cells from patients with DILI and healthy donors. 
Soluble drugs activate T cells from healthy donors in an HLA-
allele-unrestricted fashion that does not occur in patients. In 
contrast, T cells from patients with DILI are activated via a hap-
ten mechanism. The drug hapten-specific T-cell response is 
HLA-allele-restricted.72
Strong evidence of an immune-mediated mechanism of DILI 
has recently been reported in isoniazid (INH)-induced liver in-
jury.77 Anti-INH antibody and anti-CYP autoantibodies are de-
tected in patients with liver failure, but not in patients with mild 
injury or no. Impaired immune tolerance in severe cases of 
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INH-induced liver injury has also been suggested, while mild 
cases can resolve with immune tolerance. 
It is likely that complex mechanisms can occur together in 
DILI patients, although the predominant mechanism under 
various conditions remains unclear. Several aspects of these 
mechanisms require further studies. First, protein modification 
with the drug is likely to occur, even in tolerant patients.44 The 
formation of the drug-protein complex may be an important 
initiator to induce allergic reactions, but it does not ensure T-
cell activation. Additional signals to convert an antigenic signal 
into an aberrant T-cell response may exist in patients with DILI. 
Second, the high generation rate of flucloxacillin-responsive T 
cells from HLA-B*5701+ healthy donors in vitro does not match 
with the low incidence of DILI in a general population. Only 1 
to 1,000 individuals carrying the HLA-B*5701 allele will develop 
liver injury when treated with flucloxacillin. Third, the activa-
tion of flucloxacillin-responsive T cells requires a high concen-
tration of drug, which exceeds the therapeutic dose in clinics. 
This may favor the expansion of drug-responsive T cells unre-
stricted by the HLA allele. Fourth, other manifestations, such as 
DRESS, may coexist with DILI, which could mask an alternative 
activation mechanism. 
In a recent meeting of drug hypersensitivity researchers in 
Bern, the drug-responsive T cells are also reported to be detect-
ed in patients with co-amoxiclave (amoxicillin-clavulanate)- 
and antituberculosis drug-induced liver injuries. Amoxicillin- 
or clavulanic acid-responsive T-cell clones isolated from pa-
tients with DILI show drug-specific T-cell proliferation in a 
dose- and antigen processing-dependent manner, suggesting a 
hapten mechanism for antigen presentation.78 The proliferative 
response of amoxicillin-specific CD4+ T-cell clones is restricted 
by MHC class II, especially the DR molecule.78 This finding is 
consistent with the previous identification of HLA-DRB1*1501 
as a risk genotype for co-amoxiclave-induced liver injury.12,19,20,79 
In patients with antituberculosis drug-induced liver injury, en-
hanced proliferation and IFN-γ secretion are found in PBMC 
against isoniazid, but not rifampicin, pyrazinamide, or etham-
butol. Antituberculosis drugs may be the next target for immu-
nological studies on DILI. 
Animal model of idiosyncratic DILI
In vitro studies with human PBMC provide knowledge of the 
nature of the immune response and the signals that are specific 
for DILI; however, little information can be acquired regarding 
the pathways that are activated when the immune response de-
velops and/or the ability of T cells to damage an intact liver. 
Thus, an animal model that mimics the human condition (de-
layed onset, similar pathogenesis) would greatly assist the study 
of mechanisms of idiosyncratic DILI. To date, however, at-
tempts to develop such models have been largely unsuccessful. 
This is because of difficulties in mimicking human drug expo-
sure and the absence of relevant human HLA alleles. Moreover, 
the co-stimulatory/co-inhibitory signals that occur during a 
pathogenic immune response have not yet been defined and 
are therefore almost impossible to model. 
In 2003, Shenton et al.80 described a rat model of nevirapine-
induced tissue injury. Rats developed a mild-moderate skin 
rash following drug exposure. The reaction has a delayed onset 
(2-3 weeks), is dose-dependent, is strain-specific, and is only 
detected in a portion of animals. Furthermore, rechallenge with 
nevirapine results in the development of clinical symptoms 
much more rapidly. Each of these phenomena is indicative of 
an immune-mediated reaction against the drug, and indeed 
depletion of CD4+ T-cells was found to decrease the incidence 
of skin rash. Importantly, rats do not develop DILI, which is ob-
served in several nevirapine-exposed human patients. 
To investigate whether the absence of DILI involves an ac-
quired tolerance against the drug-derived antigen, Metushi et 
al.81,82 administered the hepatotoxin amodiaquine and anti- cy-
totoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies 
to programmed cell death-1 (PD-1) knockout mice. Both 
CTLA4 and PD-1 are known to be negative regulators of anti-
gen-specific T-cell responses. Interestingly, mice exposed to 
amodiaquine develop liver injury with a delayed onset. In sub-
sequent experiments, it will be interesting to see whether simi-
lar observations are detected with other DILI drugs, including 
those that cause reactions in human patients expressing specif-
ic HLA alleles.
Predictive biomarkers of DILI
Clinicians and drug manufacturers recognize 2 different types 
of DILI. Dose-dependent intrinsic DILI can be detected during 
the early stages of drug development, while idiosyncratic DILI 
not showing simple dose-dependency cannot be predicted. 
Over 1,000 approved drugs have been associated with DILI. 
The most common serum biomarkers for the detection of liv-
er injury are serum total bilirubin and the enzyme activity of 
ALT, ALP, and aspartate aminotransferase (AST). Increased en-
zyme activities and total bilirubin may represent liver injury 
and declining liver function.83 The enzyme activity of ALT in se-
rum has been considered the gold standard to predict hepato-
cellular damage;84 however, the elevated activity is actually as-
ymptomatic and not specific for liver injury. ALT activity can 
also increase from other extrahepatic injuries, such as skeletal 
muscle injury due to inflammation.85 Serum alkaline phospha-
tase is not liver- specific and can be increased in other disease 
states.84 Total bilirubin is an insensitive marker of liver disease. 
A considerable effort to identify novel biomarkers of DILI has 
been made by the international research consortia of clinicians 
and scientists, such as the Safer and Faster Evidence-based 
Translation (SAFE-T) and the Mechanism Based Integrated 
Systems for the Prediction of Drug Induced Liver Injury (MIP-
DILI). The main purpose is to identify a more specific, reliable, 
non-invasive biomarker for early prediction, treatment, or pre-
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vention of DILI. In advanced technologies on “-omics” plat-
form fields, a few promising biomarkers have been identified to 
date.86 Circulating glutamate dehydrogenase representing mi-
tochondrial leakage may be used as a DILI biomarker since it is 
released during hepatocellular necrosis.83 High-mobility group 
box 1 has been identified as an early serum indicator of hepato-
cellular necrosis in acute liver injury.87 Liver-enriched microR-
NA, miR-122, may be a promising biomarker for the prediction 
of DILI because it is highly restricted to the liver, detected dur-
ing the early stages of hepatocellular damage, and well-corre-
lated with histopathologic features.88 It is a more sensitive bio-
marker compared to currently used clinical chemistry parame-
ters for acute and chronic drug-induced liver injury.89,90 
Future perspectives
The mechanism involved in the development of DILI is com-
plicated, and the hypotheses that exist today are likely to be 
only a portion of the mechanisms involved in DILI. A better un-
derstanding of underlying diseases could lead to improved pre-
clinical tests to detect whether a new drug candidate has the 
potential to cause DILI as well as the form of DILI. Further-
more, the development of diagnostic tests based on the drug-
specific immune response may lead to the prediction of DILI in 
the early stages of a reaction and identification of a culprit drug 
in a patient taking multiple drugs. 
HLA genotypes serve as biomarkers of DILI as well as other 
genotypes, such as those of drug-metabolizing enzymes and 
transporters, and the use of more genetic markers could be ef-
fective in preventing idiosyncratic DILI. The next challenge will 
be to identify rare variants that confer the susceptibility of DILI 
using next generation sequencing and to understand how the 
pattern of genetic variants predicts disease susceptibility. 
Recent studies have attempted to develop an in vitro model 
system based on differentiated hepatocyte-like cells (HLCs) 
from human-induced pluripotent stem cells (hiPSC) to study 
and screen for idiosyncratic DILI.91 In addition, hiPSC-derived 
HLCs from individuals suffering from idiosyncratic DILI could 
be used for mechanistic studies on the pathophysiology of idio-
syncratic DILI. However, further efforts to refine the differentia-
tion and characterization of HLCs in vitro will be applicable for 
safety pharmacology and toxicology assessment.
New developments in the fields of bioinformatics, genomics, 
and proteomics will expedite the identification of predictive 
biomarkers of DILI. These studies can be used to improve early 
diagnosis and generate novel therapies for DILI. 
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